Thomas Jefferson University

Jefferson Digital Commons
Farber Institute for Neurosciences Faculty
Papers

Farber Institute for Neurosciences

9-1-2009

Human amniotic fluid stem cells do not differentiate into
dopamine neurons in vitro or after transplantation in vivo.
Angela E Donaldson
Department of Neurology, Farber Institute for the Neurosciences, Thomas Jefferson University

Jingli Cai
Department of Neurology, Farber Institute for the Neurosciences, Thomas Jefferson University

Ming Yang
Department of Neurology, Farber Institute for the Neurosciences, Thomas Jefferson University

Lorraine Iacovitti
Department of Neurology, Farber Institute for the Neurosciences, Thomas Jefferson University

Follow this and additional works at: https://jdc.jefferson.edu/farberneursofp
Part of the Neurology Commons

Let us know how access to this document benefits you
Recommended Citation
Donaldson, Angela E; Cai, Jingli; Yang, Ming; and Iacovitti, Lorraine, "Human amniotic fluid stem
cells do not differentiate into dopamine neurons in vitro or after transplantation in vivo." (2009).
Farber Institute for Neurosciences Faculty Papers. Paper 7.
https://jdc.jefferson.edu/farberneursofp/7
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Farber Institute for Neurosciences Faculty Papers by an authorized administrator of the
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

ORIGINAL RESEARCH REPORT

STEM CELLS AND DEVELOPMENT
Volume 18, Number 7, 2009
© Mary Ann Liebert, Inc.
DOI: 10.1089/scd.2008.0300

Human Amniotic Fluid Stem Cells Do Not Differentiate Into
Dopamine Neurons In Vitro or After Transplantation In Vivo
Angela E. Donaldson, Jingli Cai, Ming Yang, and Lorraine Iacovitti

Although embryonic stem (ES) cells can generate dopamine (DA) neurons that are potentially useful as a cell
replacement therapy in Parkinson’s disease (PD), associated ethical and practical concerns remain major stumbling blocks to their eventual use in humans. In this study, we examined human amniotic fluid stem (hAFS)
cells derived from routine amniocenteses for their potential to give rise to DA neurons in vitro and following
transplantation into the 6-hydroxydopamine-lesioned rat brain. We show that undifferentiated hAFS cells constitutively expressed mRNAs and proteins typical of stem cells but also cell derivatives of all three germ layers,
including neural progenitors/neurons (nestin, β-tubulin III, neurofilament). Additionally, these cells expressed
mRNAs of an immature DA phenotype (Lmx1a, Pitx-3, Nurr1, Aldh1a1) but not the corresponding proteins.
Importantly, treatment with DA differentiation factors using a variety of protocols did not further promote the
development of fully differentiated DA neurons from hAFS cells. Thus, Lmx1a, Aldh1a1, AADC, TH, and DAT
proteins were not detected in hAFS cells in culture or after transplantation into the PD rat brain. Moreover, by
3 weeks after implantation, there were no surviving AFS cells in the graft, likely as a result of an acute immunorejection response, as evidenced by the abundant presence of CD11+ macrophage/microglia and reactive
GFAP+ astrocytes in the host brain. Taken together, these results suggest that further studies will be needed to
improve differentiation procedures in culture and to prolong cell survival in vivo if hAFS cells are to be useful
as replacement cells in PD.

Introduction

O

ver the last two decades, there has been intense focus
on the potential use of stem cells to replace dead or dying
neurons in neurodegenerative diseases such as Parkinson’s
disease (PD). Toward this end, stem cells from a variety of
embryonic and adult sources have been studied in vitro and
in vivo using a host of differentiation protocols (for review,
refs. 1,2). To date, partial success has been achieved. While
adult human bone marrow stromal stem cells (hMSCs) are
capable of acquiring some dopaminergic traits, they do not
fully trans-differentiate into dopamine (DA) neurons nor
do they survive long term transplantation into the brain
[3]. Greater success has instead been achieved using human
embryonic stem (hES) cells that can be differentiated into
neurons of a DA phenotype in vitro and in vivo, and which
can ameliorate motor deficits after transplantation into an
animal model of PD [4–14].
However, ongoing legal, ethical, and practical issues
associated with ES cells remain major stumbling blocks to

their eventual use in humans. Consequently, researchers
continue to search for more practical sources of stem cells
in humans. One such alternative source that has received
much interest of late is human amniotic fluid collected
during routine amniocenteses. Amniotic fluid contains a
variety of cell types derived from both fetal and amnion tissues, ~1% of which are believed to be amniotic fluid stem
(AFS) cells [15,16]. Thus, it was of great interest when Atala
and colleagues [17] reported recently that they had successfully established human stem cell lines from amniotic
fluid (hAFS). These hAFS cells were capable of unlimited
self-renewal and differentiation into derivatives of all three
germ layers in culture, sharing overlapping but not identical properties with pluripotent hES cells [17]. Of particular
significance, was their ability to express traits of a neural
lineage (i.e., nestin and β-tubulin III) in culture and after
transplantation into the brain. Unlike their hES cell counterparts, hAFS cells reportedly showed no sign of tumorigenicity in vivo. Thus, hAFS cell lines could provide an abundant,
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nontumor-forming source of human stem cells free of ethical dilemma that could be used in cell replacement therapies
for diseases like PD. Therefore, in this study, we investigated
whether cells derived from hAFS cell lines could indeed be
differentiated into neurons, particularly those that express
traits of a DA phenotype either in vitro or after transplantation in vivo into PD rats.

Materials and Methods
Cell propagation/differentiation in culture
Cells of the AFS-A1 (Passage 15) and AFS-H1 (Passage 18)
cells lines were generously supplied by A. Atala (Wake
Forest University, NC). Human AFS cells were cultured on
polystyrene (Petri) dishes in α-MEM medium (Invitrogen)
containing 18% Chang’s Medium B, 2% Chang’s Medium
C (Irvine Scientific), ES-qualified 15% FBS (Invitrogen), 1%
L-glutamine and 1% Penicillin/Streptomycin (Invitrogen) at
37°C with 5% CO2 atmosphere. Cells were passaged at 70%
confluence at a dilution of 1:4 to 1:6 and used for experiments
at Passage 15–21 for A1 cells and Passage 18–27 for H1 cells.
For differentiation protocols, cells were grown either according to Protocol A in defined serum-free (DM) media plus 20
ng/mL of basic fibroblast growth factor (bFGF) for 1 week
followed by 1 week in 10 ng/mL aFGF, 200 nM TPA, 20 μM
DA, 0.25 mM IBMX plus 50 μM forskolin; or Protocol B as
described in Results. Essentially, neurosphere-like clusters
were generated from 5 × 105 cells grown in suspension in
DM + Noggin (200 ng/mL) and maintained for 5–7 days (as
described previously in ref. 6). Cells were gently lifted with
a P1000 pipette and seeded in Ultra-low attachment dishes
(Corning). In addition, cells were plated at a high density
(100,000–150,000 cells in 25 μL seeded droplet) on chamber
slide wells coated with polyornithine, 100ng/cm2 human
collagen IV, 10 ng/mL laminin or 5 μg/mL human plasma
fibronectin and incubated with a variety of other differentiation protocols (Table 2).

6-OHDA lesions
Animals were maintained in accord with the Office
of Animal Resources at Thomas Jefferson University and
IACUC policies. As described previously [14,18], 12 Fischer
344 rats (Taconic) were made Parkinsonian for these studies. Briefly, rats were anesthetized with sodium pentobarbital [30 mg/kg, intraperitoneally (i.p.)], placed in a stereotaxic
apparatus (Kopf Instruments) and a 26-gauge Hamilton
syringe containing 6-OHDA (Sigma; 20 μg/mL in 4 μL phosphate-buffered saline (PBS) containing 0.2 mg/mL ascorbate) was lowered into the right median forebrain bundle
(AP: −4.4mm, ML: −1.2mm, DV: −7.8 mm from bregma).
The 6-OHDA solution was gradually injected at a rate of
1 μL/min. All lesions were verified 3 and 6 weeks later by
assessment of rotational behavior in an automated rotometer system (Columbus Instruments) following amphetamine
challenge (5 mg/kg, i.p.). Only rats with consistent and stable lesions (>10 ipsilateral turns/min on multiple tests) were
used for transplantation studies.
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~1 × 106 of undifferentiated (N = 4) or semi-differentiated
[cells treated with bFGF in Protocol A (N = 2) or neurospheres generated in Protocol B (N = 8)] hAFS cells, deposited at three stereotaxic levels (AP: +1.2mm, ML: −2.7 mm,
DV: −5.4 mm, −4.9 mm and −4.2 mm) in the striatum on
the side ipsilateral to the 6-OHDA lesion as described previously [13]. All transplant recipients received cyclosporine A
(15 mg/kg, i.p.) daily, beginning 1–2 days before transplantation. Animals with hAFS cell transplants were sacrificed at
3 days, 1 and 3 weeks and brains sectioned for immunocytochemical analysis.

Immunocytochemistry
Cultures were rinsed twice in PBS, fixed with 4% paraformaldehyde and immunocytochemically stained (details
described in 14). Antibodies used were: mouse monoclonal
anti-Nestin (Chemicon 1:250), rabbit polyclonal anti-homeobox
transcription factor 1 alpha (Lmx1; gift from Dr. M. German
1:1,000), mouse monoclonal anti-β-tubulin III (R&D Systems
1:400), goat polyclonal anti-retinaldehyde dehydrogenase
(Aldh1a1) (Novus Biologicals 1:500), rabbit polyclonal antityrosine hydroxylase (TH) (Pel-Freez 1:150), sheep polyclonal
anti-TH (Abcam 1:1000), rabbit polyclonal anti-glial fibrillary
acidic protein (GFAP) (Chemicon 1:1000), rabbit polyclonal antiaromatic l-amino acid decarboxylase (AADC) (Protos Biotech
1:50) mouse monoclonal anti-dopamine transporter (DAT)
(Chemicon 1:50). All secondary antibodies were Alexa Fluor
antibodies from Invitrogen; donkey anti-rabbit 594, 1:300; donkey anti-rabbit 488, 1:300; donkey anti-mouse 594, 1:300; donkey anti-mouse 488, 1:300.Cultures were mounted in ProLong
Gold antifade reagent with DAPI (Invitrogen). Stained cells
were counted in representative fields (N = 5) on duplicate
slides and expressed as a percentage of the total cells.
For immunocytochemical staining in transplantation
experiments, rats were perfused with 500 mL of cold (4°C)
periodate-lysine-paraformaldehyde (4%). Brains sections
were cut at 30 μm on a freezing microtome and processed
for immunocytochemistry as described previously [6,14].
Antibodies were used as above except for the following
differences: (β-tubulin III; 1:200), HNA (1:40); GFAP from
Chemicon (1:200) and mouse monoclonal anti-CD11 from
BD Biosciences (1:25). Brain sections were analyzed along the
length of the graft using a Nikon-Scanalytics Image System
or a Zeiss LSM510 Confocal Image System.

RNA isolation and cDNA synthesis
Total RNA was isolated directly from freshly collected hAFS neurospheres and H9 StgIV cells with TRIzol
(Invitrogen), a modification of the guanidine isothiocyanatephenol-chloroform extraction method. cDNA was synthesized by using 100 ng total RNA in a 20 μL reaction with
Superscript III (Invitrogen) and oligo (dT)12–18 (Invitrogen).
One microliter of RNase H (Invitrogen) was added to each
reaction tube, and the tubes were incubated for 20 min at
37°C before proceeding to polymerase chain reaction (PCR).

PCR amplifi cation
Transplantation procedures
Animals with verifiable lesions (>10 ipsilateral turns/
min) were implanted with a total of 10 μL of PBS containing

A 0.5 μL cDNA template was used in a 20 μL reaction
volume with the PCR master mix (Promega).The cycling
parameters were: 94°C, 1 min; 55°C, 1 min; 72°C, 1min, for
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30 cycles. The PCR cycles were preceded by an initial denaturation of 3 min at 94°C and followed by a final extension
of 10 min at 72°C (details in ref. 14) (primers are listed in
Table 1).

Results
Undifferentiated hAFS cells were propagated as described
previously [17]. We first tested various differentiation protocols (see Table 2 for complete list), beginning with several
used successfully to differentiate DA neurons either from
hMSCs [3] or hES cells [6] in our laboratory. Undifferentiated
hAFS cells, grown according to the mesenchymal protocol
(Protocol A) (Fig. 1A), were fed a defined media containing 20 ng/mL of bFGF for 1 week followed by an additional
week in the DA differentiation cocktail (10 ng/mL aFGF, 200
nM TPA, 20 μM DA, 0.25 mM IBMX plus 50 μM forskolin) as
described previously [3,18,19]. This media often produced a
high level of cell death after several days in culture, possibly

Table 1.
Gene name

Accession
no.

Oct4

BC117435

Sox2

NM_003106

Nestin

NM_006617

Vimentin

NM_003380

βIIItubulin

NM_006086

NEFH

NM_021076

GFAP

NM_002055

AFP

NM_001134

FN

NM_212482

Lmx1a

AY078391

Aldh1a1

NM_000689

Pitx3

NM_005029

Nurr1

NM_006186

Girk2

NM_002240

AADC

NM_000790

DAT

NM_001044

TH

NM_199292

GAPDH

NM_002046

due to the presence of potentially toxic substances like forskolin. Using the hES differentiation protocol developed in
this laboratory (Protocol B) (Fig.1B), hAFS cells were first
incubated with 200 ng/mL noggin for 4 days to promote the
formation of clusters of neural progenitors. This stage was
next followed by a 1 week expansion phase during which
cells were propagated as neurospheres in suspension before
plating as dissociated cells. Unlike hES cells, hAFS cells did
not readily form compact spheres nor did they require subcloning, suggesting that the nestin+ cells in these spheres
were not dividing as robustly as in hES cell cultures. Finally,
when hAFS neurospheres were dissociated into single cells
for further differentiation in adherent cultures, we found
poor attachment to substrates (polyornithine, laminin, fibronectin, collagen type IV) previously used to adhere other
types of stem cells [3,6,14,17]. Adherence of a small number of dissociated neurosphere (Protocol B) hAFS cells only
when polyornithine-coated dishes were also treated with
fibronectin.

Primers
Primer sequence

CTTGCTGCAGAAGTGGGTGGAGGAA
CTGCAGTGTGGGTTTCGGGCA
ATGCACCGCTACGACGTGA
CTTTTGCACCCCTCCCATTT
CAGCGTTGGAACAGAGGTTGG
TGGCACAGGTGTCTCAAGGGTAG
GACACTATTGGCCGCCTGCAGGATGAG
CTGCAGAAAGGCACTTGAAAGC
GAACAGCACGGCCATCCAGG
CTTGGGGCCCTGGGCCTCCGA
TGCGGCGCCACCACCAG
GGCGGCCATCTCCCACTTG
GTGGGCAGGTGGGAGCTTGATTCT
CTGGGGCGGCCTGGTATGACA
AAATACATCCAGGAGAGCCA
CTGAGCTTGGCACAGATCCT
TGTTATGGAGGAAGCCGAGGTTTT
CCCGATGCAGGTACAGTCCCAGAT
CTCAATTTAGTGTATGAAGAGG
CTACATTCTCTTGGCTGGAC
CTGAAATGTGACCCCCAAGT
TGACAAGCAGACATGACATCC
GGACTAGGCCCTACACACAGA
TCCGCGCACGTTTATTTC
GGCTGAAGCCATGCCTTGT
GTGAGGTCCATGCTAAACTTGACA
CAACAATGGCCAAGCTGACA
TCCGATCTCGGCTGATGTG
GGGACCACAACATGCTGCTC
CCACTCCATTCAGAAGGTGCC
TCCATCAACTCCCTGACGAGCTTC
CTGGGCCGCTGCCCGGTCATCTGC
TCATCACCTGGTCACCAAGTT
GGTCGCCGTGCCTGTACT
ACAGTCAGCCGCATCTTCTT
GACAAGCTTCCCGTTCTCAG

Product
size (bp)
169
437
389
418
244
452
388
417
150
372
280
151
150
150
145
500
125
259
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Table 2.

Differentiation of Amniotic Fluid Stem (AFS) Cells Using Various Treatment Protocols

Treatment
Undifferentiated AFS Cells
Defined Media – 7 div
Protocol A
DM + bFGF (20 ng/mL) – 7 div
DM + aFGF + DA + TPA + IBMX + Forskalin – 7 div
*High cell death
Protocol B
DM + Noggin (200 ng/mL) – 5–7 div
Lift as neurospheres and seed in ultra-low attachment dish
Neurocult proliferation media – 7 div
Plate on P-Orn/fibronectin and diff in:
DM + cAMP (1μM) + Ascorbate – 2 div
DM + cAMP (500μM) + Ascorbate – 2 div
DM + bFGF (20 ng/mL) + Noggin (200 ng/mL) – 7 div

Nestin

Lmx1a

Sox2

Aldh1a1

βtubIII

TH

GFAP

2+

–

–

1+

1+

–

–

2–3+

–

–

1+

1+

–

–

4+
2+

–
–

–
–

2+
1+

1+
3+

–
–

–
–

3–4+

2+

–

–

–

1+

–

–

4+

–

–

2+

1+

–

–

3–4+

–

–

–

1+

–

–

DM + bFGF (20 ng/mL) – 7 div
DM + SHH (200 ng/mL) + FGF8 (100 ng/mL) + bFGF
(20 ng/mL) – 7 div
*Cell death at 5 div
NB media + B27 + SHH (250 ng/mL) + FGF8 (100 ng/mL)
+ bFGF (50 ng/mL) – 7 div
DM + B27 + BDNF (25 ng/mL) + forskolin (15 μM) +
DA(10 μM) – 7 div
*No change in morphology

2+

DM + B27 + Wnt1 (10 ng/mL) + bFGF (20 ng/mL) – 7 div

4+

–

–

–

1+

–

DM + B27 + ascorbate (200 μM) + cAMP (500 μM)
*High cell death

2+

–

–

–

–

–

DM + bFGF (20 ng/mL) + Wnt5A (100 ng/mL) – 7 div
*Nestin + FoxA2 double-labeled cells (1–2+)

4+

–

–

–

1+

–

DM + substantia nigra conditioned media (1:1) – 7 div
*No change in cells

2+

–

–

–

–

–

DM + glial conditioned media (1:1) – 7 div
*No change in cells

2+

–

–

–

–

–

2+

–

–

–

–

–

DM + aFGF + DA + TPA + IBMX + Forskalin – 7 div
*Cells died within 5 div

DM + H9 stg 5 conditioned media (1:1)
*Cells died within 4–5 days
DM + MEF conditioned media (1:1) – 7 div
*No change in cells

AFS cells were stained for the presence of cell type specific markers after differentiation using a particular treatment protocol. For
cultures treated with conditioned media, defined media was incubated for 3 days on cultures of P1 rat glia, E14 rat substantia nigra,
mouse embryonic fibroblasts (MEF from specialty media), and stage V hES cells as described in ref. 6. Cultures of viable cells were
stained with the markers listed and evaluated for the intensity of staining as follows: none (–), lightly (1+), moderately (2–3+), or darkly
(4+) stained cells.

To assess the degree of differentiation achieved by these
cells at various stages in these treatment protocols, we next
examined the expression of stem cell (Oct4, Sox2), neural
progenitor (nestin, vimentin), neural [β-tubulin III, neurofilament (NEFP)] glial (GFAP), endodermal [α-fetoprotein
(AFP)] and mesodermal (fibronectin:FN) markers as well as
specific markers of the DA system, including the DA transcription factors (Lmx1a, Nurr1, Pitx3), enzymes (Aldh1a1,
AADC, TH), transporters (DAT) and channels [G-protein

regulated inwardly rectifying potassium channel (Girk2)] by
PCR. We found that undifferentiated hAFS cells expressed
not only stem cell transcripts, but also markers of the three
germ layers, including those associated with an endodermal
(AFP), mesodermal (FN) and neurectodermal lineage (nestin, β-tubulin III, human NEFH). Of particular interest was
expression of mRNAs normally associated with more differentiated neuronal phenotypes (Fig. 2). Consequently, early
markers of a DA phenotype, such as Lmx1a and Aldh1a1,

1007

HUMAN AMNIOTIC FLUID STEM CELLS DO NOT GENERATE DOP
A

Protocol A

Propagation of
undifferentiated AFS cells

Expansion of nestin
positive progenitor cells

Nstn/Dapi

Neuronal differentiation

β-TubIII

Nstn/Dapi

Culture
Days
0

14

DM⫹aFGF⫹DA⫹TPA⫹IBMX⫹Forskolin

DM⫹bFGF

Chang’s Medium

B

7

Protocol B

Selection of nestin
positive progentior cells

Propagation of
undifferentiated AFS cells

Expansion of progentior
cells as neurospheres

Nstn/Dapi

Nstn/Dapi

Culture
Days
0

Chang’s Medium

4

DM⫹Noggin

11
Neurocult NS-A
Proliferation Medium

FIG. 1. Depiction of various treatments used to differentiate human amniotic fluid stem (hAFS) cells into dopamine (DA)
neurons in culture. (A) Protocol A was previously used to differentiate DA neurons from human mesenchymal stem cells
(hMSCs) and was described in detail in ref. 3. (B). Protocol B was previously used to differentiate DA neurons from hES cells
and was described in ref. 6.
were readily detected by reverse transcription (RT)-PCR
while more mature DA markers (AADC, TH, DAT) were not.
When hAFS cells were further differentiated by either protocol, we continued to see many of the same transcripts as
in the undifferentiated state, with the exception of the disappearance of the endodermal marker AFP (Fig. 2). In addition, with Protocol A, the stem cell marker Oct 4 and the

DA-specifying gene Lmx1a were down regulated (Fig. 2).
However, hAFS neurospheres generated in Protocol B continued to express Lmx1a as well as several other transcripts
associated with a more differentiated DA phenotype (i.e.,
Pitx3, Nurr1 and Girk2; Fig. 2).
Next, sister cultures were stained with antibodies to
many of these cell types and DA-specific markers. Similar

Oct4
Sox2
Nestin
Vimentin
␤III tubulin
NEFH
GFAP
AFP
FN
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Lmx1a
Aldh1a1
Pitx3
Nurr1
Girk2
AADC
DAT
TH
G3PDH

FIG. 2. RT-PCR analysis of various stages in human amniotic fluid stem (hAFS) cell differentiation. Markers of stem
cells (Oct4, Sox2), neural progenitors (nestin, vimentin),
neurons (βIIItubulin, NEFH), glia (GFAP), ectoderm (AFP),
mesoderm (FN), as well as DA-related markers (Lmx1a,
Aldh1a1, Pitx3, Nurr1, Girk2, AADC, DAT, TH) were compared in undifferentiated (AFS-undiff) or partially differentiated cells (AFS-semidiff with bFGF according to Protocol A)
or following neurosphere formation (in Protocol B). Positive
controls taken from human embryonic stem (hES) cells differentiated into DA neurons (as described in ref. 14) were
also included for AADC and TH as these were not expressed
in AFS cells.

to our RT-PCR results, using immunocytochemistry, we
found that progenitor protein nestin was robustly expressed
in 20–40% of individual undifferentiated hAFS cells (Fig.
1A, 1B insets; Table 2). With further differentiation, cells
changed in morphological shape but continued to express
nestin. Moreover, the proportion of nestin+ cells increased,
with the greatest number (>80%) found in semi-differentiated cultures (Protocol A) and in neurospheres (Protocol B)
(Table 2). In contrast, relatively few (<20%) undifferentiated
or semi-differentiated hAFS cells expressed the early neuron
marker β-tubulin III (Fig. 3). The number of β-tubulin III+
cells did however increase (40–60%) after the final differentiation step in Protocol A. Because in Protocol B dissociated
neurosphere cells did not attach well to adherent substrates,
we could not assess the degree of neuronal differentiation in
these cultures (Table 2).
When semi-differentiated or fully differentiated cultures
were further probed for the expression of DA marker proteins, importantly, no positively stained cells were observed
regardless of their state of differentiation or the protocol
used (Table 2). Thus, Lmx1a-staining cells were not detected
by immunocytochemistry in these cultures despite detection of Lmx1a mRNA in pooled cell cultures. Likewise, neither Aldh1a1, AADC, TH nor DAT positive staining was
observed in undifferentiated or differentiated AFS cells
(Table 2), unlike other stem cell derivatives studied in our
laboratory [3,6,14,18].
We next sought to determine whether transplantation of
hAFS cells into the brain would further foster their development into DA neurons. Thus, undifferentiated (N = 4) and
semi-differentiated hAFS cells (cells semi-differentiated
with bFGF in Protocol A; N = 2 or neurospheres generated
in Protocol B; N = 8) were transplanted into the striata of
hemi-lesioned (6-OHDA) immunosuppressed rats on the

denervated side. Fully differentiated cells were not used in
transplantation experiments (i.e., Protocol A) because process-bearing neurons do not generally survive harvest and
implantation. Of the 12 animals that were transplanted, only
one graft of neurospheres (Protocol B) contained viable hAFS
cells, as evidenced by the presence of the human nuclear
antigen marker (HNA) (Fig. 4A), and only at their earliest
time point examined (3 days after implantation). As shown
in Fig. 4A, surviving cells exhibited an immature morphology, expressing markers of neural progenitors (nestin; Fig.
4A) and neurons (β-tubulin III) but not DA neuron traits
(Lmx1a or TH; data not shown). Importantly, when grafts
of these same cells were examined at 3 weeks after implantation, no hAFS cells remained at the implantation site (note
the absence of HNA staining in Fig. 4B) nor were HNA+ cells
found in surrounding brain regions. Residual nestin staining observed in the vicinity of the graft was instead likely
due to the presence of host brain progenitors. When these
brains were further examined for the presence of reactive
glia and macrophage/microglia, we found copious staining
for their respective type-specific markers, GFAP and CD11 in
host cells adjacent to the graft site at 3 days (data not shown)
and 3 weeks (Fig. 4C and D) after implantation.

Discussion
This study has examined hAFS cells as an abundant,
practical, and ethical source of stem cells to generate neurons
for cell replacement therapies. In particular, our laboratory
is interested in the differentiation of hAFS cells into functional DA neurons to replace cells lost in PD. We show here
that undifferentiated hAFS cells from established cells lines
[17] constitutively expressed mRNAs and proteins typical of
stem cells but also cell derivatives of all three germ layers,
including neural progenitors/neurons (nestin, β-tubulin III,
NEFH). Additionally, these undifferentiated cells expressed
specific transcripts appropriate to an immature DA phenotype (Lmx1a, Pitx-3, Nurr1, Aldh1a1). However, treatment
of hAFS cells with various DA differentiation factors using
a number of published protocols did little to advance their
development into fully differentiated DA neurons. Only
cells grown as neurospheres and differentiated as described
in Protocol B exhibited an increase in the expression of some
DA transcripts. When AFS neurospheres were transplanted
in vivo, cells did not survive more than several days following their transplantation into the PD rat brain, likely
due to an intense immunorejection response in host tissue.
Transplanted cells that did survive in the short term, however, did not express detectable levels of any of DA proteins
(Lmx1a, Aldh1a1, AADC, TH, DAT).
The fact that hAFS cells, even after incubation with
known neuron-promoting differentiation factors [3–14,20],
continued to express transcripts of non-neuronal cell types
indicates that hAFS cells behave quite differently from other
pluripotent stem cell sources. Thus, hES cells that initially
express transcripts from all three germ layers, if grown
under the same conditions used here (Protocol B), will
proceed down a neural progenitor pathway to selectively
become neurons [4–14]. Likewise, adult stem cells (hMSCs)
grown under similar culture conditions (Protocol A) downregulate mesenchymal (FN) transcripts with the expression
of neuronal markers (nestin, β-tubulin III) [3,20]. In contrast, in this study, undifferentiated hAFS cells expressed
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A

B

β-Tub III/Dapi

Undiff

Protocol A

β-Tub III/Dapi

Semidiff

C

β-Tub III/Dapi

Protocol A

Diff

FIG. 3. Immunocytochemical localization of β-tubulin III in amniotic fluid stem (AFS) cells at various stages of differentiation. AFS cells were stained with β-tubulin III antibodies in the undifferentiated (Undiff) state (A) or after semi-differentiation (Semidiff) (B) and full differentiation (Diff) (C) using procedures described in Protocol A (as shown in Fig. 1). While
many cells express β-tubulin III in all stages, unseen in imaged fields are other cells which do not express the neuronal
marker. Note the change in cell shape as cells become more differentiated.

transcripts for nestin, β-tubulin III and FN, with no shift in
the mRNA expression profile toward a neuronal fate after
further differentiation in culture. Although differentiated
hAFS cells acquired a neuronal like appearance and stained
for neuronal marker proteins, it remains uncertain whether
these cells can in fact function as neurons.
Further distinguishing the behavior of hAFS cells from
other stem cell types was their acquisition of DA traits.
Earlier studies on hMSCs and hES cells demonstrated that
DA-related markers that were absent in undifferentiated
cells could be partially or fully induced in vitro and in vivo
using Protocols A and B, respectively [3,6,14,20]. In contrast,
in this study, even in the undifferentiated state, hAFS cells
expressed a number of mRNAs normally associated with
DA-specified progenitors/neurons but could not be further
induced to complete their DA differentiation by incubation
using published protocols (Table 2). Although in Protocol B,
neurosphere cells did not survive plating and growth on differentiation medium in order to assess DA protein expression, using Protocol A (and other differentiation schemes)

A

NSTN&HNA

3 Days

B

there was no immunocytochemical evidence for Lmx1a,
Aldh1a1, AADC, TH, or DAT in these cells, regardless of their
differentiation status or their expression of DA mRNAs. The
reasons for this disparity remain unknown but suggest that
cells may be trapped in a primitive state, unable to produce
critical proteins of a differentiated neuronal subtype using
these treatment protocols. Consistent with this possibility is
the fact that mature DA phenotypic traits, such as the expression of the key DA rate-limiting enzyme TH or the second
enzyme in DA biosynthesis AADC, were never observed
at either the transcriptional or protein levels in these cells.
Nonetheless, the DA-associated Girk2 channel [21–23] was
detected by RT-PCR both in this study and by Atala and colleagues who also demonstrated its functionality (i.e., barium
sensitivity) in culture [17]. As Girk2 expression has also been
reported in a variety of non-DA neurons [24–26), proof that
its expression here represents the acquisition of a bona fide
DA neuronal trait will require experimental corroboration
by other methods. Additionally, using different AFS lines
and a different DA differentiation protocol, Tsai et al. [27]

NSTN&HNA

3 Weeks

C

GFAP&CD11

D

LV

3 Weeks

3 Weeks

GFAP&CD11

FIG. 4. Immunocytochemical localization of phenotypic markers at various times after transplantation of amniotic fluid stem (AFS) neurospheres
into the striata of 6-OHDA treated rats. Cells were
double labeled for: nestin and HNA at 3 days (A)
and nestin and HNA (B) or GFAP and CD11 (C
and D) at 3 weeks after transplantation. Panel D
is a higher power view of the graft site shown in
Panel C. Sections were mounted in ProLong Gold
antifade reagent with DAPI (Invitrogen) and analyzed along the length of the graft using a NikonScanalytics Image System or a Zeiss LSM510
Confocal Image System. Bars = 100 μM.

1010
showed that small quantities of DA could be detected in
the media following KCl-stimulated release. However, they
did not provide evidence that AFS cells possessed the DA
synthetic machinery (TH, AADC) to manufacture DA as
opposed to simply taking up and re-releasing DA found in
their (serum-containing) media.
Although the initial report describing these hAFS lines
reported long-term survival of cells after transplantation into the lateral ventricles of newborn mice [17], in our
transplantation studies, hAFS cells did not persist in the
adult PD rat brain. This was likely due to the acute immunorejection of cells as evidenced by the copious expression
of the microglial/macrophage marker CD11 and the reactive
glial marker GFAP in host cells near the site of transplantation. This rejection response occurred despite the immunosuppression of rats with Cyclosporin A using a regimen
that has successfully supported the long-term survival of
other xenotransplanted human stem cells [3,6,14]. Similar
to our observations, others using the same cell lines, also
found an intense immunorejection response after hAFS
transplantation into the immunosuppressed and immunodeficient rat myocardium [28]. Although hAFS cells were
originally thought to be non-immunogenic because of their
lack in major histocompatibility complex class II molecules,
there is now evidence for expression of T-cell co-stimulatory
molecules (normally found on antigen presenting cells) that
may contribute to their immunorejection after transplantation [28]. Possibly, as a result of the relative immaturity of the
newborn immune system, these molecules are less effective
thereby allowing the survival of transplanted hAFS cells
into the perinatal brain [17]). Another possible explanation
for the rejection of these cells may stem from their heterogeneity, with mesodermal derivatives causing an intense
immune/inflammatory response in the brain [3]. Of the few
cells that did survive in the short term after transplantation
into the brain, there was little evidence of maturation into
fully differentiated neurons or incorporation into surrounding host tissues. A similar lack of neuronal differentiation
and integration has recently been observed following the
transplantation of human cord blood into the retina [29].
In sum, our studies have demonstrated that although
hAFS cells constituitively express a number of traits normally associated with neural progenitors/immature neurons, they cannot be induced to acquire a fully differentiated
DA neuronal phenotype in vitro or in vivo. In addition,
these cells are highly immunogenic, inducing an acute rejection response after transplantation into the adult immunosuppressed rat brain. Taken together, these results suggest
that further studies will be needed to improve differentiation procedures in culture and to prolong cell survival in
vivo if hAFS cells are to be useful as replacement cells in PD
therapy.
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